Mounjaro®
Starting from £179.99/mo
Start journey Learn moreFeeling unusually tired after starting tirzepatide is common, particularly in the first few weeks. Fatigue appears in the clinical trial data and in the NHS patient information for tirzepatide as one of the recognised side effects, sitting alongside the more widely discussed nausea and digestive changes. For most people it is mild, linked to the body adapting to a lower calorie intake and to the medicine's effects on gastric emptying, and it tends to ease as treatment continues. The question worth sitting with is not simply whether you will feel tired, but what kind of tiredness is normal, what might signal something worth investigating, and what practical steps can actually help. This page works through each of those considerations, because making that distinction matters when you are taking a prescription medicine that deserves proper clinical oversight.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The relationship between tirzepatide and tiredness has a few distinct threads, and understanding them helps you decide whether what you are feeling is within the expected range. The medicine works as a dual GIP and GLP-1 receptor agonist, slowing the speed at which the stomach empties and reducing appetite in ways that are genuinely novel — it is the only dual-agonist weight-loss medicine licensed in the UK. When you eat less and absorb nutrients more slowly, your body takes time to recalibrate its energy supply. That recalibration period, particularly in the first four weeks or after a dose step-up, is when tiredness tends to peak.
There is also a more direct mechanism. GLP-1 receptor activity influences the central nervous system, and some people notice a general heaviness or low motivation that feels different from ordinary tiredness. This is not a reason to stop treatment without speaking to your prescriber, but it is worth logging, when it starts, how long it lasts each day, and whether it tracks with meals or dose timing. That detail is genuinely useful at your next review. If you want to understand how Mounjaro fatigue tends to present and why it happens, that dedicated page goes into the mechanisms in more depth. For a fuller look at Mounjaro's side-effect profile as a whole, the picture is broader than fatigue alone.
One thing that catches people out: dehydration. If nausea or vomiting reduces your fluid intake, energy levels drop quickly. Drinking enough plain water through the day is one of the simplest things you can do, not glamorous advice, but consistently underestimated.
This is the practical decision the page title is really asking about. Most tirzepatide-related fatigue is self-limiting. It eases within one to three weeks and does not prevent daily life. The version worth escalating looks different. It is fatigue that is getting worse rather than better as the weeks pass, or tiredness that arrives alongside other symptoms: severe or persistent stomach pain (especially pain that radiates toward the back), yellowing skin or eyes, dark urine, or a rapid heartbeat. Those combinations need prompt medical assessment.
The MHRA Yellow Card scheme allows patients to report suspected side effects directly, and doing so contributes to the ongoing safety monitoring of medicines like tirzepatide, which still carries a Black Triangle (▼) designation indicating it is subject to additional surveillance. You do not need to be certain a symptom is drug-related to file a report; suspected is enough.
People who live with conditions like hypothyroidism, anaemia, or sleep disorders sometimes find their existing fatigue is harder to distinguish from a treatment effect. If that applies to you, reading about whether Mounjaro does cause fatigue or whether something else may be at play can help you frame a clearer conversation with your prescriber. Our clinical team covers this kind of detail in every review, not as an afterthought.
There is reasonable evidence that protein adequacy, hydration and sleep quality each influence how pronounced tiredness feels during GLP-1-based treatment. When appetite falls substantially, it is easy to under-eat protein without noticing, and low protein intake compounds fatigue in a way that has nothing to do with the medicine specifically. Aiming to prioritise protein at each meal (even when appetite is low) tends to help more than simply eating less of everything.
Timing matters for some people too. A small number of patients find tiredness is most pronounced in the hours after their weekly injection. Scheduling the dose for an evening when a quieter following morning is possible (rather than, say, the night before a demanding day) can reduce the disruption. It is also worth knowing that energy and mood are closely linked during treatment, and if low motivation is part of what you are experiencing, the page covering how tirzepatide can affect mood addresses that dimension directly. For those wondering whether fatigue changes as doses increase, the question of whether tirzepatide causes fatigue and how that changes across the titration schedule is covered in more detail separately.
Sleep itself feeds into the loop. Tirzepatide can improve sleep quality for people with obstructive sleep apnoea (one of its licensed comorbidity indications) so some patients actually find energy improves over time despite initial tiredness. That longer arc is worth holding onto when the first few weeks feel heavy.
Seek same-day medical attention if tiredness is accompanied by severe abdominal pain, difficulty breathing, signs of a serious allergic reaction (swelling of the face, lips or throat), or a dramatic change in vision. These are not the expected side effects of dose adjustment; they need urgent assessment that goes beyond a pharmacy conversation.
For fatigue that is significant but not urgent, your prescriber is the right first call. Tirzepatide is a prescription-only medicine, and the clinical relationship does not end at the dispensing stage. At nume, every repeat order is reviewed by a GPhC-registered Independent Prescriber before it is dispensed, which means there is a structured opportunity to raise how you are feeling, not just whether you want to continue. If you are dealing with persistent low energy alongside treatment that is not improving, that review is the right moment to say so.
You can also report any suspected side effect via the MHRA's Yellow Card at any point. The NHS patient information page for tirzepatide lists the full side-effect profile, and the NHS tirzepatide guidance sets out clearly which symptoms need prompt medical review. If questions about fatigue are part of a wider conversation about whether treatment is right for you, checking your eligibility through a free consultation is the natural starting point.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.